Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) (ORCHARD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03944772
Recruitment Status : Recruiting
First Posted : May 10, 2019
Last Update Posted : November 17, 2020
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments.

Condition or disease Intervention/treatment Phase
Non-Small Cell Lung Cancer Drug: Osimertinib Drug: Savolitinib Drug: Gefitinib Drug: Necitumumab Drug: Durvalumab Drug: Carboplatin Drug: Pemetrexed Drug: Alectinib Drug: Selpercatinib Phase 2

Detailed Description:

This is an open-label, multicentre, multi-drug, biomarker-directed Phase 2 platform study in patients with advanced non-small cell lung cancer (NSCLC) harbouring an epidermal growth factor receptor (EGFR)-sensitizing mutation whose disease has progressed on first-line monotherapy with osimertinib.Treatment options for these patients are limited. Novel treatments for these patients are urgently required.

This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 182 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Phase 2 platform study in patients with advanced Non-Small Lung Cancer harbouring an epidermal growth factor receptor (EGFR)-sensitizing mutation with evidence of radiological progression following first-Line osimertinib therapy. This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments. The study will be conducted in three groups (Groups A, B and C). Patient allocation to a study treatment within each group will be based on tumour molecular profile. Biomarker positive patients will be allocated to a biomarker-matched study treatment in Group A, patients without a biomarker will be allocated to a study treatment in Group B and patients with histological transformed disease or a biomarker amenable to therapies not currently available in ORCHARD will be allocated to Group C (observational; patients managed in accordance with local practice).
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Biomarker-directed Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy.
Actual Study Start Date : June 25, 2019
Estimated Primary Completion Date : November 29, 2023
Estimated Study Completion Date : November 29, 2023

Resource links provided by the National Library of Medicine

Drug Information available for: Osimertinib

Arm Intervention/treatment
Experimental: Module 1: Osimertinib + Savolitinib
The patients in this group will receive osimertinib taken in combination with savolitinib
Drug: Osimertinib
Osimertinib given orally at 80 mg once daily
Other Name: TAGRISSO

Drug: Savolitinib
Savolitinib will be given orally at 300 mg or 600mg once daily

Experimental: Module 2: Osimertinib + Gefitinib
The patients in this group will receive osimertinib taken in combination with gefitinib
Drug: Osimertinib
Osimertinib given orally at 80 mg once daily
Other Name: TAGRISSO

Drug: Gefitinib
Gefitinib given orally at 250 mg once daily
Other Name: Iressa

Experimental: Module 3: Osimertinib + Necitumumab
The patients in this group will receive osimertinib taken in combination with necitumumab
Drug: Osimertinib
Osimertinib given orally at 80 mg once daily
Other Name: TAGRISSO

Drug: Necitumumab
Necitumumab given IV at 800 mg on Day 1 and Day 8 of every 3-week cycle
Other Name: Portrazza

Experimental: Module 4: Carboplatin + Pemetrexed + Durvalumab)
The patients in this group will receive platinum-containing doublet (carboplatin + pemetrexed) taken in combination with durvalumab.
Drug: Durvalumab
Durvalumab given IV at 1500 mg on Day 1 of every cycle
Other Name: IMFINZI

Drug: Carboplatin
Carboplatin given IV on Day 1 of every 21-day cycle for up to 6 cycles

Drug: Pemetrexed
Pemetrexed given IV at 500 mg/m2 body BSA on Day 1 of every cycle

No Intervention: Observational Cohort: No study drug

Patients in this group will not receive study treatment but receive further anticancer care (Standard of Care therapy or other experimental therapies) or supportive care, as clinically indicated, in accordance with local practice.

With Group C, the aim is to understand the clinical course and/or outcome for the overall clinical population after progression on first-line monotherapy with osimertinib.

Experimental: Module 5: Osimertinib + Alectinib
The patients in this group will receive osimertinib taken in combination with alectinib
Drug: Osimertinib
Osimertinib given orally at 80 mg once daily
Other Name: TAGRISSO

Drug: Alectinib
Alectinib given orally at 600mg twice daily and for Japanese patients at 300mg twice daily.
Other Name: Alecensa

Experimental: Module 6: Osimertinib + Selpercatinib
The patients in this group will receive osimertinib taken in combination with selpercatinib
Drug: Osimertinib
Osimertinib given orally at 80 mg once daily
Other Name: TAGRISSO

Drug: Selpercatinib
Selpercatinib given orally at 160mg twice daily
Other Name: Loxo-292




Primary Outcome Measures :
  1. Objective response rate (ORR) [ Time Frame: Measured from first dose until confirmed response or progression. For each patient this is expected to be 3 months on average ]
    The percentage of patients with a confirmed investigator-assessed complete or partial response according to Response Evaluation Criteria In Solid Tumours (RECIST) 1.1. Patients will be followed up every 6 weeks (±1 week) for the first 24 weeks and every 9 weeks thereafter until RECIST 1.1 defined disease progression or cessation of study treatment (if treating beyond progression).


Secondary Outcome Measures :
  1. Progression-free survival (PFS) [ Time Frame: Measured from first dose until progression. For each patient this is expected to be 6 months on average ]
    The time from first dose until the date of objective disease progression or death (by any cause in the absence of progression). Patients will be followed up every 6 weeks (±1 week) for the first 24 weeks and every 9 weeks thereafter until RECIST (Response Evaluation Criteria In Solid Tumours)1.1 defined disease progression or cessation of study treatment (if treating beyond progression).

  2. Duration of response (DoR) [ Time Frame: Measured from response until progression. For each patient this is expected to be 6 months on average ]
    The time from the date of first response until date of disease progression or death in the absence of disease progression. Patients will be followed up every 6 weeks (±1 week) for the first 24 weeks and every 9 weeks thereafter until RECIST 1.1 defined disease progression or cessation of study treatment (if treating beyond progression).

  3. Overall survival (OS) [ Time Frame: Measured from first dose until death or final cohort data cut-off. For each patient this is expected to be 20 months on average ]
    The time from the date of the first dose of study treatment until death due to any cause.

  4. Plasma concentrations of therapeutic agents [ Time Frame: Pre-dose and 1 hour post-dose blood samples on Day 1 of Cycles 1, 3 (Cycle 2 for durvalumab), 6 for all therapeutic agents and a sample at the 90-day safety follow up for durvalumab only. (One Cycle = 21 or 28 days, depending on treatment). ]
    Blood samples will be collected at various timepoints to evaluate the sparse pharmacokinetics of study therapeutic agents.

  5. Plasma concentrations of therapeutic agents [ Time Frame: Pre-dose and serial post-dose blood samples (1 hour, 2 hours, 4 hours, 6 hours, 8 hours) on Day 15 of Cycle 1 for alectinib and selpercatinib only. ]
    Blood samples will be collected at various timepoints to evaluate the serial pharmacokinetics of study therapeutic agents

  6. Incidence of Treatment-emergent adverse events (AEs) and serious adverse events (SAEs) as characterized and graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event [CTCAE] v5 [ Time Frame: Continuously from first dose to end of safety follow up after study treatment discontinuation (approximately up to 21 Months) ]
    To evaluate safety and tolerability of each study treatment



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 130 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria applicable to all study treatment modules (Groups A/B):

  • Non-Small Cell Lung Cancer (NSCLC) with the following features:

    • Locally advanced or metastatic disease (i.e. advanced NSCLC) not amenable to curative surgery or radiotherapy at study entry.
    • Histologically or cytologically confirmed adenocarcinoma of the lung harbouring epidermal growth factor receptor (EGFR) mutation(s) known to be associated with tyrosine kinase inhibitors (TKI) sensitivity at diagnosis.
    • Received only 1 line of therapy, with single-agent osimertinib, for advanced NSCLC, with clinical benefit as judged by investigator discretion.
    • Evidence of radiological disease progression on first-line monotherapy with osimertinib 80mg once daily.
  • Suitable for a mandatory biopsy defined as having an accessible tumour and a stable clinical condition that will allow the patient to tolerate the procedure. The biopsy should be performed within 60 days prior to the planned first dose of study treatment.
  • Patients must have measurable disease per Response Evaluation Criteria In Solid Tumours (RECIST) 1.1.
  • World Health Organisation (WHO) performance status 0 or 1 with no deterioration between screening and the first dose of study treatment.
  • A minimum life expectancy of 12 weeks.
  • Ability to swallow and retain oral medication and have adequate venous access.
  • Provision of archival tumour tissue for exploratory research (if such tissue/sample is available, its provision is mandatory).
  • Ability and willingness to comply with the study and follow-up.
  • Adequate coagulation parameters, defined as: International Normalisation Ratio (INR) <1.5 × upper limit of normal (ULN) and activated partial thromboplastin time <1.5 × ULN unless patients are receiving therapeutic anti-coagulation which affects these parameters.
  • Patients with known tumour thrombus or deep vein thrombosis are eligible if clinically stable on low molecular weight heparin, factor Xa inhibitors or thrombin inhibitors for ≥2 weeks.
  • Willingness to adhere to the study treatment-specific contraception requirements.

Exclusion Criteria applicable to all study treatment modules (Groups A/B):

  • Patients whose disease has progressed within the first 3 months of osimertinib treatment
  • Patients must not have experienced a toxicity(-ies) that led to permanent discontinuation or dose reduction of prior osimertinib or have any unresolved toxicities from prior osimertinib treatment greater than CTCAE (Common Terminology Criteria for Adverse Event) Grade 1 at the time of starting study treatment
  • Patients must not have discontinued osimertinib >60 days prior to the first dose of study treatment
  • Prior or concurrent treatment with any systemic anticancer therapy for locally advanced/metastatic NSCLC including chemotherapy, biologic therapy, immunotherapy, or any investigational drug (exceptions do apply)
  • Major surgery within the 28 days prior to the first dose of study treatment except:

    • After minor surgery, at least 7 postoperative days must elapse before study treatment is initiated.
    • After placement of vascular access, this waiting period is not required.
  • Receipt of live attenuated vaccine within 30 days prior to the first dose of study treatment.
  • Treatment with warfarin/coumarin analogues within 7 days prior to the first dose of study treatment
  • Diagnosis of small cell lung cancer (SCLC) or squamous cell carcinoma (SCC)
  • Spinal cord compression, symptomatic and unstable brain metastases, except for those patients who have completed definitive therapy, are not on steroids, have a stable neurologic status for at least 2 weeks after completion of the definitive therapy and steroids.
  • Allogenic organ transplantation
  • As judged by the investigator, any evidence of severe or uncontrolled systemic disease or evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study.
  • History of another primary malignancy except for:

    • Malignancy treated with curative intent and with no known active disease for at least 2 years before the first dose of study treatment, and with low potential risk for recurrence.
    • Adequately treated nonmelanoma skin cancer or lentigo maligna without evidence of disease
    • Adequately treated carcinoma in situ without evidence of disease.
    • Localised non-invasive primary disease under surveillance.
  • Active infection, including infections with hepatitis B virus, hepatitis C virus, or human immunodeficiency virus (exceptions apply)
  • Pregnancy or breastfeeding in female patients
  • Any of the following cardiac criteria:

    • Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG
    • Unstable atrial fibrillation or unstable cardiac arrhythmia with a ventricular rate >100 bpm on an ECG at rest.
    • Uncontrolled hypertension
    • Uncontrolled angina or acute coronary syndrome within 6 months prior to screening.
    • At risk for brain perfusion problems or stroke, or transient ischemic attack in the last 6 months prior to screening
    • Symptomatic heart failure
    • Prior or current cardiomyopathy.
    • Severe valvular heart disease
  • Inadequate bone marrow reserve or organ function
  • Creatinine clearance <50 mL/min, calculated by Cockcroft-Gault equation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03944772


Contacts
Layout table for location contacts
Contact: AstraZeneca Clinical Study Information Center 1-877-240-9479 information.center@astrazeneca.com
Contact: Cancer Study Locator (For US sites only) 1-877-400-4656 astrazeneca@emergingmed.com

Locations
Layout table for location information
United States, California
Research Site Recruiting
Duarte, California, United States, 91010
Research Site Recruiting
Los Angeles, California, United States, 90048
Research Site Recruiting
Sacramento, California, United States, 95817
Research Site Recruiting
Santa Monica, California, United States, 90404
Research Site Recruiting
Santa Rosa, California, United States, 95403
United States, Connecticut
Research Site Recruiting
New Haven, Connecticut, United States, 06510
United States, Illinois
Research Site Recruiting
Chicago, Illinois, United States, 60612
United States, Maryland
Research Site Recruiting
Baltimore, Maryland, United States, 21224
United States, Massachusetts
Research Site Recruiting
Boston, Massachusetts, United States, 02114
Research Site Recruiting
Boston, Massachusetts, United States, 02215
United States, New York
Research Site Recruiting
New York, New York, United States, 10017
Research Site Recruiting
New York, New York, United States, 10032
United States, Texas
Research Site Recruiting
Houston, Texas, United States, 77030
United States, Washington
Research Site Recruiting
Seattle, Washington, United States, 98109
Denmark
Research Site Recruiting
Herlev, Denmark, 2730
Research Site Recruiting
Odense C, Denmark, 5000
Research Site Recruiting
Vejle, Denmark, 7100
Japan
Research Site Recruiting
Chuo-ku, Japan, 104-0045
Research Site Recruiting
Fukuoka-shi, Japan, 812-8582
Research Site Recruiting
Koto-ku, Japan, 135-8550
Research Site Recruiting
Nagoya-shi, Japan, 464-8681
Research Site Recruiting
Osaka-shi, Japan, 541-8567
Research Site Recruiting
Wakayama-shi, Japan, 641-8510
Korea, Republic of
Research Site Recruiting
Seongnam-si, Korea, Republic of, 13620
Research Site Recruiting
Seoul, Korea, Republic of, 03722
Research Site Recruiting
Seoul, Korea, Republic of, 05505
Research Site Recruiting
Seoul, Korea, Republic of, 06351
Netherlands
Research Site Recruiting
Amsterdam, Netherlands, 1066 CX
Research Site Recruiting
Amsterdam, Netherlands, 1081 HV
Research Site Recruiting
Maastricht, Netherlands, 6229 HX
Research Site Recruiting
Nijmegen, Netherlands, 6525 GA
Research Site Recruiting
Rotterdam, Netherlands, 3015 GD
Norway
Research Site Recruiting
Drammen, Norway, 3004
Research Site Recruiting
Oslo, Norway, N-0310
Research Site Recruiting
Trondheim, Norway, 7030
Spain
Research Site Recruiting
A Coruña, Spain, 15006
Research Site Recruiting
Barcelona, Spain, 08025
Research Site Recruiting
Barcelona, Spain, 08036
Research Site Recruiting
Madrid, Spain, 28041
Research Site Recruiting
Madrid, Spain, 28046
Research Site Recruiting
Sevilla, Spain, 41009
Sweden
Research Site Recruiting
Stockholm, Sweden, 171 76
Research Site Suspended
Uppsala, Sweden, SE-751 85
Sponsors and Collaborators
AstraZeneca
Investigators
Layout table for investigator information
Principal Investigator: Helena A Yu, MD Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT03944772    
Other Study ID Numbers: D6186C00001
First Posted: May 10, 2019    Key Record Dates
Last Update Posted: November 17, 2020
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access Criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
URL: https://astrazenecagroup-dt.pharmacm.com/DT/Home

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by AstraZeneca:
Non-small cell lung cancer
NSCLC
Phase II
Platform study
Biomarker-directed
Durvalumab
Osimertinib
Savolitinib
Gefitinib
Necitumumab
Platinum-containing doublet
Pemetrexed
EGFR positive
Carboplatin
Alectinib
Selpercatinib
TKI-resistant
MET amplification
MET exon 14 skipping
EGFR
EGFR C797X
EGFR G724X
EGFR L718X
EGFR exon 20 insertion
EGFR amplification
BRAF V600E
ALK rearrangement
RET rearrangement
ROS1 rearrangement
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Carboplatin
Pemetrexed
Durvalumab
Gefitinib
Osimertinib
Necitumumab
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors
Antineoplastic Agents, Immunological
Protein Kinase Inhibitors